Effect of <font color="red">rosuvastatin_4</font> <font color="red">monotherapy_4</font> <font color="red">or_3</font> <font color="red">in_3</font> <font color="red">combination_3</font> <font color="red">with_3</font> <font color="red">fenofibrate_4</font> <font color="red">or_4</font> <font color="red">ω-3_4</font> <font color="red">fatty_4</font> <font color="red">acids_4</font> <font color="red">on_1</font> <font color="red">lipoprotein_2</font> <font color="red">subfraction_1</font> <font color="red">profile_1</font> in patients with mixed <font color="red">dyslipidaemia_1</font> <font color="red">and_1</font> <font color="red">metabolic_1</font> <font color="red">syndrome_1</font> <font color="red">._1</font> 
<br>
<br> BACKGROUND Raised <font color="red">triglycerides_1</font> <font color="red">(_1</font> <font color="red">TG_1</font> <font color="red">)_1</font> <font color="red">,_1</font> decreased <font color="red">high_1</font> <font color="red">-_1</font> <font color="red">density_1</font> <font color="red">lipoprotein_1</font> <font color="red">cholesterol_1</font> <font color="red">(_1</font> <font color="red">HDL_1</font> <font color="red">-_1</font> <font color="red">C_1</font> <font color="red">)_1</font> levels and a predominance of <font color="red">small_1</font> <font color="red">dense_1</font> <font color="red">low_1</font> <font color="red">density_1</font> <font color="red">lipoproteins_1</font> <font color="red">(_1</font> <font color="red">sdLDL_1</font> <font color="red">)_1</font> are characteristics of the <font color="red">metabolic_1</font> <font color="red">syndrome_1</font> ( MetS ) . 
<br> OBJECTIVE To compare the effect of <font color="red">high_2</font> <font color="red">-_2</font> <font color="red">dose_2</font> <font color="red">rosuvastatin_5</font> <font color="red">monotherapy_4</font> <font color="red">with_1</font> <font color="red">moderate_2</font> <font color="red">dosing_2</font> <font color="red">combined_2</font> <font color="red">with_2</font> <font color="red">fenofibrate_5</font> <font color="red">or_3</font> <font color="red">ω-3_4</font> <font color="red">fatty_4</font> <font color="red">acids_4</font> <font color="red">on_3</font> <font color="red">the_3</font> <font color="red">lipoprotein_3</font> <font color="red">subfraction_2</font> <font color="red">profile_1</font> in patients with mixed <font color="red">dyslipidaemia_1</font> and MetS. 
<br> METHODS We previously randomised patients with <font color="red">low_2</font> <font color="red">-_2</font> <font color="red">density_2</font> <font color="red">lipoprotein_2</font> <font color="red">cholesterol_2</font> <font color="red">(_1</font> <font color="red">LDL_1</font> <font color="red">-_1</font> <font color="red">C_1</font> <font color="red">)_1</font> <font color="red">>_1</font> <font color="red">160_1</font> <font color="red">and_1</font> <font color="red">TG_1</font> <font color="red">>_1</font> <font color="red">200_1</font> <font color="red"> _1</font> <font color="red">mg_1</font> <font color="red">/_1</font> <font color="red">dl_1</font> to <font color="red">rosuvastatin_5</font> <font color="red">monotherapy_4</font> <font color="red">40_2</font> <font color="red"> _2</font> <font color="red">mg_2</font> <font color="red">/_2</font> <font color="red">day_2</font> <font color="red">(_1</font> <font color="red">R_2</font> <font color="red">group_2</font> <font color="red">,_2</font> <font color="red">n_1</font> <font color="red">=_1</font> <font color="red">30_1</font> <font color="red">)_1</font> <font color="red">or_1</font> <font color="red">rosuvastatin_5</font> <font color="red">10_3</font> <font color="red">mg_3</font> <font color="red">/_3</font> <font color="red">day_3</font> <font color="red">combined_2</font> <font color="red">with_2</font> <font color="red">fenofibrate_5</font> <font color="red">200_2</font> <font color="red">mg_2</font> <font color="red">/_2</font> <font color="red">day_2</font> <font color="red">(_2</font> <font color="red">RF_2</font> <font color="red">group_2</font> <font color="red">,_2</font> <font color="red">n_1</font> <font color="red">=_1</font> <font color="red">30_1</font> <font color="red">)_1</font> <font color="red">or_2</font> <font color="red">ω-3_3</font> <font color="red">fatty_3</font> <font color="red">acids_3</font> <font color="red">2_1</font> <font color="red">g_1</font> <font color="red">/_1</font> <font color="red">day_1</font> <font color="red">(_1</font> <font color="red">Rω_2</font> <font color="red">group_2</font> <font color="red">,_2</font> <font color="red">n_1</font> <font color="red">=_1</font> <font color="red">30_1</font> <font color="red">)_1</font> <font color="red">._1</font> In the present study , only patients with MetS were included <font color="red">(_1</font> <font color="red">24_1</font> <font color="red">,_1</font> <font color="red">23_1</font> <font color="red">and_1</font> <font color="red">24_1</font> <font color="red">in_1</font> <font color="red">the_1</font> <font color="red">R_1</font> <font color="red">,_1</font> <font color="red">RF_1</font> <font color="red">and_1</font> <font color="red">Rω_1</font> <font color="red">groups_1</font> <font color="red">respectively_1</font> <font color="red">)_1</font> <font color="red">._1</font> At baseline and after 12 weeks of treatment , the <font color="red">lipoprotein_1</font> <font color="red">subfraction_1</font> profile was determined by <font color="red">polyacrylamide_1</font> <font color="red">3%_1</font> <font color="red">gel_1</font> <font color="red">electrophoresis_1</font> <font color="red">._1</font> 
<br> RESULTS The mean <font color="red">LDL_1</font> size was significantly increased in all groups . This change was more prominent with <font color="red">RF_2</font> than with other treatments in parallel with its greater hypotriglyceridemic capacity ( p < 0.05 compared with R and Rω ) . A decrease in insulin resistance by <font color="red">RF_1</font> was also noted . Only <font color="red">RF_2</font> significantly raised <font color="red">HDL_1</font> <font color="red">-_1</font> <font color="red">C_1</font> <font color="red">levels_1</font> <font color="red">(_1</font> <font color="red">by_1</font> <font color="red">7.7%_1</font> <font color="red">,_1</font> <font color="red">p_1</font> <font color="red"><_1</font> <font color="red">0.05_1</font> <font color="red">)_1</font> by increasing the cholesterol of small <font color="red">HDL_1</font> particles . The <font color="red">cholesterol_1</font> of larger <font color="red">HDL_1</font> subclasses was significantly increased by <font color="red">R_2</font> <font color="red">and_1</font> <font color="red">Rω._2</font> 
<br> CONCLUSIONS All <font color="red">regimens_1</font> increased mean <font color="red">LDL_1</font> size ; <font color="red">RF_1</font> was the most effective . A differential effect of treatments was noted on the <font color="red">HDL_1</font> subfraction profile .